1. Home
  2. LDI vs SENS Comparison

LDI vs SENS Comparison

Compare LDI & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$0.60

Market Cap

542.4M

Sector

Finance

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$9.90

Market Cap

496.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
SENS
Founded
2010
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Industrial Machinery/Components
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
542.4M
496.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LDI
SENS
Price
$0.60
$9.90
Analyst Decision
Sell
Strong Buy
Analyst Count
3
4
Target Price
$3.00
★ $18.38
AVG Volume (30 Days)
★ 6.6M
617.1K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $16,389,000.00
Revenue This Year
$17.58
$74.15
Revenue Next Year
$13.99
$58.60
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 19.85
52 Week Low
$0.61
$0.41
52 Week High
$3.80
$10.48

Technical Indicators

Market Signals
Indicator
LDI
SENS
Relative Strength Index (RSI) 27.81 61.88
Support Level N/A $8.45
Resistance Level $1.19 $10.07
Average True Range (ATR) 0.06 0.45
MACD -0.01 -0.03
Stochastic Oscillator 3.53 71.52

Price Performance

Historical Comparison
LDI
SENS

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: